Treatment for alcohol and opioid use disorders (AOUD) is feasible in primary care settings, but ongoing funding to support organizational capacity is critical for sustaining such programs.
The dopamine D3 receptor antagonist VK4-116 reduced oxycodone self-administration in rats, as well as drug-seeking behaviors after oxycodone reinstatement following withdrawal. VK4-116 did not interfere with oxycodone’s pain-relieving effects
In animal studies, α2δ-1 and its interactions with NMDA receptors in the spinal cord triggered the pain sensitivity and analgesic tolerance that occurs with chronic morphine treatment. Blocking the α2δ-1–NMDA interaction reduced opioid-induced hyperalgesia and analgesic tolerance.
Mindful Awareness in Body-Oriented Therapy (MABT) improved emotion regulation, reduced craving, and promoted abstinence in women with a history of trauma and emotional problems receiving outpatient treatment for substance use disorder.
This study showed that rats will forgo heroin and methamphetamine in favor of spending time with another rat. It also highlights the importance of incorporating voluntary choice between drugs and social rewards in drug addiction research.
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
Mindfulness-Oriented Recovery Enhancement (MORE) reduces opioid misuse among chronic pain patients. MORE shifts patients' attention away from drug cues and toward cues for natural rewards.